TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04158843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical resection
Description: Radical resection is performed, and the cutting edge is negative.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Description: Radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy).
Study: NCT02456428

Intervention type: DRUG
Intervention: Sulfonylureas
Description: Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: Thiazolidinediones
Description: Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study: NCT04158843

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palliative treatment
Description: Including palliative internal fixation, radiotherapy, systemic chemotherapy, endocrine therapy or targeted therapy
Study: NCT02456428

Intervention type: DRUG
Intervention: Thiazolidinediones
Description: Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: Alpha-glucosidase inhibitors
Description: Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: Alpha-glucosidase inhibitors
Description: Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: Meglitinides
Description: Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event)day.

Intervention type: DRUG
Intervention: Meglitinides
Description: Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event)day.
Study: NCT00911989

Intervention type: DEVICE
Group type: OTHER
Intervention: NOTES toolbox
Description: Using SFT for endoscope access during Transvaginal Sleeve Gastrectomy procedure. Visualization will occur through endoscope
Study: NCT00214123

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy (radiotherapy)
Description: Bin assignment based on tumor volume

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy (radiotherapy)
Description: Bin assignment based on tumor volume

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy (radiotherapy)
Description: Bin assignment based on tumor volume

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy (radiotherapy)
Description: Bin assignment based on tumor volume

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy (radiotherapy)
Description: Bin assignment based on tumor volume
Study: NCT02811874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diabetes education
Description: Diabetes education program includes: 4 theoretical sessions, 60 minutes long, taught once a week for 4 weeks, developed in the form of group classes, and given by one of the authors. The educational program content comprises (1) definition of diabetes, and identification of modifiable risk factors for type 2 diabetes, (2) non-pharmacological treatment, with emphasis on diet and exercise, (3) pharmacological therapy, including mechanism of action and side effects of anti-diabetic medications provided by the Brazilian public health system and (4) an overview of chronic diabetes complications.
Study: NCT04761211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart bra
Description: This is a patented infrared breast examination bra
Study: NCT02025296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U-healthcare
Description: use of a public switched telephone network (PSTN)-connected glucometer to measure their blood glucose level at the same frequency as the SMBG group
Study: NCT02007707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco LHW
Description: Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Eating
Description: Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about healthy eating and physical activity through 2 small-group education sessions and 2 individual phone calls over a 2-month period. Participants will receive writing information about smoking cessation resources.
Study: NCT02811874

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education in other areas
Description: Four theoretical sessions related to education in other health areas, not related to diabetes, administered during 4 weeks
Study: NCT01298908

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Operative treatment
Description: In operative treatment the great saphenous vein will be removed after flush ligation by femoral vein and stripping of the trunk.
Study: NCT00217087

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic Mucosal Resection
Description: Endoscopic mucosal resection at time of endoscopy if indicated.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic Mucosal Resection
Description: Endoscopic mucosal resection at time of endoscopy if indicated.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Photodynamic Therapy
Description: Porfimer sodium 2mg/kg
Study: NCT00911846

Intervention type: OTHER
Intervention: interview
Description: interview using questionnaires

Intervention type: OTHER
Intervention: interview
Description: interview using questionnaires

Intervention type: OTHER
Intervention: interview
Description: interview using questionnaires

Intervention type: OTHER
Intervention: interview
Description: interview using questionnaires
Study: NCT04525105

Intervention type: GENETIC
Intervention: SMAD2
Description: a family of structurally related cytokines

Intervention type: GENETIC
Intervention: SMAD2
Description: a family of structurally related cytokines
Study: NCT03359876

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15 mg, once daily

Intervention type: DRUG
Intervention: Warfarin sodium
Description: Individually adjusted dose
Study: NCT04696588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex set of kinesiotherapy of cervical spine and delicate massage
Description: Intervention:- A complex neck therapy.Treatment comprises 10 sessions performed on consecutive working days, includes four parts.~1. Active exercises of the neck, 5 minutes, first demonstrated by the physiotherapist and next the patient performs them under supervision, 5 repetitions of each of the following: cervical flexion, rotation to the left and to the right, side bending to the left and to the right, torsion to left and right.~2. Massage of cervical interspinales muscles performed by therapist 3 minutes.~3. Post Isometric Relaxation (PIR) performed by physiotherapist. 15 minutes.~4. Active neck exercises - the same as mentioned in step 1. 5 minutes. Total duration of one treatment session is around 30 minutes.
Study: NCT01450423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participation in a 10-week supervised cardio exercise program two-three times a week. Each training session consists of 10 minutes of warm-up, 20 minutes treadmill run/walk and 30 minutes cycling. Heart rate (HR) is monitored during each session. Week 1-5: at least 15 minutes above 75% of HRmax in each session. Week 6-10: at least one session above 75% HRmax.
Study: NCT00713362

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-assisted thoracoscopic surgery
Description: VATS for bullectomy and mechanical pleurodesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest tube drainage
Description: Chest tube drainage for pneumothroax
Study: NCT01055535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 125 µg intravitreal injection
Study: NCT02558374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02%
Description: 1 drop once daily (QD), PM, OU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate Ophthalmic Solution 0.5% BID
Description: 1 drop BID, AM/PM, OU

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 drop QD, AM, OU
Study: NCT04616469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment using TruNaomy rotary files
Description: Trunatomy rotary files will be used for the process of cleaning and shaping of the root canal system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment using race rotary instruments
Description: Race rotary files will be used for the process of cleaning and shaping of the root canal system
Study: NCT03906500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High schools High on Life
Description: The intervention consist of three main components.~Environmental factors of the school environment~The component targeting the high school environment consisted of two separate elements:~* Revision of school alcohol policy~* Appointment of coordinator(s) of student committees organizing events, where alcohol is sold, and student introduction committee.~Student component~The Student components consisted of three main elements:~* Online education for the student committees organizing events where alcohol is sold and the student introduction committee~* Pocket movie campaign competition~* Social norms campaign~Parent component~The parent component consisted of three separate elements:~* Parent Information Meeting~* Parent Information Folder~* Parent Information Website
Study: NCT03208231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: 40 mg/kg of VRC01 administered by subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination Antiretroviral Therapy (cART)
Description: All infants received non-study provided cART selected by their primary care provider and supplied through non-study sources (i.e., cART not provided through the study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Antiretroviral Therapy (cART)
Description: All infants received non-study provided cART selected by their primary care provider and supplied through non-study sources (i.e., cART not provided through the study).
Study: NCT02154087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HP802-247
Description: 260 µL (130 µL, one spray, of each component) containing 0.5 x 10.6 cells per mL, alternating weekly with Vehicle
Study: NCT00632853

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiation Dose Therapy
Description: 45 Gy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Radiation Dose Therapy
Description: 70 Gy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV
Study: NCT03354182

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap surgery
Description: Elevation of a flap in order to access the treated furcation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap surgery
Description: Elevation of a flap in order to access the treated furcation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-oss collagen
Description: Biomaterial for periodontal surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-gide
Description: Biomaterial for periodontal surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-gide
Description: Biomaterial for periodontal surgery
Study: NCT01724528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Standard dose PO (per os) from Day 1 to Day 7 (can be continued up to DAY 9 at investigator's discretion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Standard dose, low dose or high dose (as per investigator's judgement at the time of randomization) from DAY 1 to DAY 7 (can be continued up to DAY 9 at investigator's discretion)
Study: NCT05153057

Intervention type: OTHER
Intervention: Observational study
Description: The goal of the study is purely observational. Treatment decisions will be made by physicians according to the grading of the intraocular inflammation related to birdshot chorioretinopathy and to their consequences on visual function. These treatment decisions will be independent from the observational study.
Study: NCT00183690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Prolonged exposure therapy includes a trauma focused protocol and cognitive behavioral treatment for PTSD. Cognitive behavioral treatment includes psychoeducation, in vivo exposures, and imaginal exposures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Psychotherapy
Description: Active psychotherapy includes non-trauma focused therapy, based on time-limited psychodynamic treatment, which includes a formulation of a central issue and open-associative sessions exploring main conflicts and drives.
Study: NCT03213873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HiBalance
Description: Intervention of highly challenging balance training for 10 weeks.
Study: NCT01298908

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser ablation
Description: In intravenous laser treatment a thin laser fiber is inserted through a tiny distal entry point. The probe is guided into place using ultrasound and the procedure is performed under local tumescence anesthesia. Laser energy is delivered to seal the faulty vein.
Study: NCT03213873

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech and communication therapy
Description: Intervention conducted by speech and language therapist for 10 weeks.
Study: NCT01106846

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group A: Saline Group
Description: Saline continuous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B: 1% Ketamine group
Description: Administration of 1% ketamine intravenously.
Study: NCT00931216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integrated ANC, PMTCT, HIV services
Description: Of the 12 study clinics, 6 will be randomized to receive the intervention. At these 6 facilities, health care providers within the ANC department will be trained to also provide HIV/PMTCT care. Women testing positive within ANC clinics at integrated facilities will receive ANC, PMTCT and HIV services within the same visit/same service provider rather than being referred for HIV care and treatment.
Study: NCT00002744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT01298908

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Foam sclerotherapy
Description: Ultrasound guided foam sclerotherapy involves an injection of foam (sodium tetradecyl sulfate mixed with air according to the Thessari method) directly into the venous trunk under ultrasound control.
Study: NCT02373085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic adjusted to antibiogram
Description: A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria during the first 2 years after transplantation.
Study: NCT00002744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT00422084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine artesunate
Description: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem® (artemether lumefantrine)
Description: AL (20:120mg tablets) twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)
Study: NCT01757990

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Effect of Stevioside and Rebaudioside on plaque pH
Description: After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Effect of Stevioside and Rebaudioside on plaque pH
Description: After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Effect of Stevioside and Rebaudioside on plaque pH
Description: After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
Study: NCT00002744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy